{"product_id":"mcrb-bcg-matrix","title":"(MCRB) Seres Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Seres Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo owned commercial star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, Seres Therapeutics had no owned commercial Star: it had no in-house marketed product, and VOWST was sold to Nestlé Health Science in 2024 for $160 million upfront plus up to $125 million in milestones.\u003c\/p\u003e\n\u003cp\u003eThat means Seres no longer had an internal asset with both high share and high growth.\u003c\/p\u003e\n\u003cp\u003eIts portfolio was left to pipeline and development assets, not a cash-generating market leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZero Phase 3 asset retained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter Seres Therapeutics, Inc. sold VOWST, its pipeline remained early-stage, so no Phase 3 asset was left to support a true Star. SER-155 was still in Phase 1b, and there was no late-stage, company-owned franchise to drive high growth and strong market share. That makes this category a \"question mark\" at best, not a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-heavy profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Seres Therapeutics, Inc. still looked like a development shop: cash was aimed at clinical work, not a big sales buildout. That fits a Star only on growth, not on maturity, because the model was still R\u0026amp;D-led. With no large commercial scale to fund, the business depended on trial progress and pipeline data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo scale commercial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAfter the VOWST asset sale, Seres Therapeutics, Inc. no longer had a broad commercial setup, so the \"Star\" label did not translate into internal scale. The company did not carry a large sales force or heavy launch spend, which is why it could not keep building a big go-to-market engine. Without scale, even a strong product cannot be sustained inside Seres.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo large sales team remained\u003c\/li\u003e\n\u003cli\u003eNo major launch spend stayed in-house\u003c\/li\u003e\n\u003cli\u003eAsset sale removed commercial scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture star only if SER-155 succeeds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-155 was Seres Therapeutics, Inc.'s best shot at a future Star, but by end-2025 it was still early-stage and had zero market share. That meant the asset had potential, not proof, and its value still depended on clinical success. If the data keep holding up, it could re-rate sharply; if not, it stays a pipeline option.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo revenue yet\u003c\/li\u003e\n\u003cli\u003eEarly clinical risk remains\u003c\/li\u003e\n\u003cli\u003eZero market share by end-2025\u003c\/li\u003e\n\u003cli\u003eBinary upside from trial data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeres Had No FY2025 Stars: Pipeline-Led, Not Market-Led\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. had no Stars in FY2025: VOWST was sold in 2024 for $160 million upfront plus up to $125 million in milestones, and SER-155 was still Phase 1b with zero market share. With no owned late-stage, high-share asset, the portfolio was pipeline-led, not Star-led.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwned Star\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVOWST\u003c\/td\u003e\n\u003ctd\u003eSold in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-155\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSeres Therapeutics BCG Matrix maps its pipeline across Stars, Question Marks, Cash Cows, and Dogs to guide invest\/hold\/divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Seres Therapeutics, Inc. to quickly spot business unit priorities and pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Seres Therapeutics, Inc., making the analysis easier to verify, trust, and use in decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOWST, 2023 approved CDI franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOWST, approved by the FDA in 2023, was Seres Therapeutics’ first commercial microbiome therapy and first revenue product. It targeted recurrent Clostridioides difficile infection, a narrow U.S. market of roughly 160,000 cases a year, so it fit the \"Cash Cow\" logic better than any other Seres asset. Even so, Seres sold VOWST rights to Nestlé Health Science in 2024 for $100 million upfront, showing the franchise was valuable but not large enough to fund Seres on its own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Nestlé Health Science sale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres monetized VOWST in 2024 by selling it to Nestlé Health Science for up to $175 million, including $75 million upfront and milestone payments. That turned a commercial product into immediate cash and cut Seres Therapeutics, Inc. from the chance of building a durable in-house cash cow. The move fit a cash-preservation strategy, not a long-term growth play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow company operating leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter the VOWST divestiture, Seres Therapeutics, Inc. no longer had a large recurring product-sales base, so cash generation from operations stayed thin and uneven. In 2024, the company reported only limited revenue from remaining activities, while still carrying R\u0026amp;D and operating costs tied to its microbiome pipeline. That makes this a low operating leverage Cash Cow profile: Seres depends more on financing and deal economics than on harvest from product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormer validated microbiome platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVOWST’s FDA approval on Apr. 26, 2023 proved Seres Therapeutics, Inc. could take a microbiome therapy from science to market, so the platform had real economic value even after the sale. That proof still mattered in 2025: it acted like a balance-sheet asset, not a live cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA approval validated the platform.\u003c\/li\u003e\n\u003cli\u003eSale monetized that validation.\u003c\/li\u003e\n\u003cli\u003e2025 value was strategic, not operating.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn BCG terms, this was a cash-cow-like legacy strength only in valuation terms, because the platform had already been converted into cash and lost its direct commercial pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo mature recurring revenue base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Seres Therapeutics, Inc. had only one approved product, VOWST, and no second mature franchise to generate steady, low-growth cash. That means it had no true Cash Cow in-house: revenue stayed dependent on a single launch, while 2025 filings still showed a small, volatile base rather than the scale of a mature portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne approved product: VOWST\u003c\/li\u003e\n\u003cli\u003eNo second cash-generating brand\u003c\/li\u003e\n\u003cli\u003eNo broad mature revenue base\u003c\/li\u003e\n\u003cli\u003eCash flow remained launch-dependent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeres Lost Its Only Cash Cow—And 2025 Looked Launch-Dependent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. had no true Cash Cow by 2025. VOWST was the only approved product, but Seres sold the franchise to Nestlé Health Science in 2024 for up to $175 million, including $75 million upfront, so the company turned a potential recurring seller into one-time cash. By end-2025, revenue still looked launch-dependent and thin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eKey Cash Cow Signal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eVOWST sale\u003c\/td\u003e\n\u003ctd\u003e$75M upfront; up to $175M total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e1 product: VOWST\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eCash cow status\u003c\/td\u003e\n\u003ctd\u003eNo in-house recurring cash engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSeres Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Seres Therapeutics, Inc. BCG Matrix document you'll receive after purchase. The full file is delivered without changes, so what you see here is what you get. No placeholders, no demo content—just the complete report ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-401, metastatic melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-401 in metastatic melanoma showed no commercial traction by end-2025, with no disclosed product sales or market share and no visible late-stage momentum. In BCG terms, it fits a \"Dog\": low share, low growth, and far from scale. For Seres Therapeutics, that means the program added little to 2025 revenue or cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-262, Clostridioides difficile infection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-262 is a Dogs asset in Seres Therapeutics, Inc. BCG Matrix terms: it is an older Clostridioides difficile infection program that was eclipsed by VOWST, which got FDA approval in 2023. With no clear market leadership, no disclosed commercial runway, and no evident 2025\/2026 growth path, SER-262 looks like a weak legacy asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-287, ulcerative colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-287 for ulcerative colitis was still early-stage and, in Seres Therapeutics, Inc.'s FY2025 view, had no approved product, no revenue, and no visible market share. The IBD space was crowded in 2025, with multiple approved biologics and small-molecule options already competing for patients. With no clear differentiation versus these established therapies, SER-287 fits the Dog bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSER-301, ulcerative colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-301, Seres Therapeutics, Inc.'s early ulcerative colitis microbiome program, had 0 commercial revenue and no market footprint, so it fit a Dogs profile. It needed heavy R\u0026amp;D spend with no clear path to near-term cash flow, which made the risk\/reward weak. In BCG terms, it tied up capital in a low-share, uncertain-payoff asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 sales; no launch\u003c\/li\u003e\n\u003cli\u003eHigh R\u0026amp;D burden\u003c\/li\u003e\n\u003cli\u003eUnclear payoff\u003c\/li\u003e\n\u003cli\u003eLow-return Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy non-core microbiome work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Seres Therapeutics, Inc. still had legacy non-core microbiome programs and collaborations outside its main commercial path. These exploratory assets usually burn cash through R\u0026amp;D and do not add revenue, so they fit the Dog bucket unless a partner or new data turns them around.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow strategic fit\u003c\/li\u003e\n\u003cli\u003eCapital drain, weak payback\u003c\/li\u003e\n\u003cli\u003eNeeds revival or exit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeres’ FY2025 Dogs: No Sales, No Traction, No Near-Term Turnaround\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Seres Therapeutics, Inc.’s Dogs stayed weak: SER-401, SER-262, SER-287, and SER-301 had no disclosed product sales, no market share, and no clear near-term commercialization path. SER-262 was eclipsed by VOWST, which was FDA-approved in 2023, while SER-287 and SER-301 remained early and cash-hungry. These assets fit the Dog bucket because they tied up R\u0026amp;D with little payoff.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-401\u003c\/td\u003e\n\u003ctd\u003e0 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-262\u003c\/td\u003e\n\u003ctd\u003eNo market traction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-287\u003c\/td\u003e\n\u003ctd\u003eEarly-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-301\u003c\/td\u003e\n\u003ctd\u003eNo revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-155, Phase Ib\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-155 was Seres Therapeutics, Inc.’s lead active program by end-2025, and it sat in Phase Ib with market share still at zero. The asset still needed proof of efficacy and durability, but that also left a large upside if later data readouts hold up. Seres ended 2025 with $0 commercial revenue and only this early-stage program driving its BCG \"Question Mark\" profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic hematopoietic stem cell transplant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogeneic hematopoietic stem cell transplant fits a Question Mark for Seres Therapeutics, Inc. because SER-155 targets infection prevention in a very high-risk setting, but the clinical path is still not clear. The unmet need is large: allogeneic transplant is used in more than 20,000 patients a year in the U.S. and Europe, and infection remains a major cause of early morbidity and death. SER-155 could matter, but it still has to prove durable efficacy and safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBloodstream infection reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. is betting on bloodstream infection reduction in very fragile patients, where even a small drop in serious infections can matter. In SER-155, Seres reported a 77% relative reduction in bloodstream infections versus controls in allo-HSCT patients. If that signal holds in larger studies, the commercial upside could be meaningful; for now, it is still a high-risk question mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGraft-versus-host disease prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGVHD remains a major transplant risk, affecting about 30% to 50% of allogeneic stem-cell recipients and driving high morbidity and cost. A microbiome therapy that lowers GVHD could scale fast, so this is a clear \"Question Mark\" for Seres Therapeutics, Inc.\u003c\/p\u003e\n\u003cp\u003eBut by end-2025, Seres Therapeutics, Inc. had not proven that benefit in the clinic or won a commercial standard-of-care role, so the upside was still speculative. That matters because Seres Therapeutics, Inc. ended 2025 with no established GVHD revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need, high upside\u003c\/li\u003e\n\u003cli\u003eClinical proof still missing by end-2025\u003c\/li\u003e\n\u003cli\u003eNot yet a cash-generating asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture microbiome consortium pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAt end-2025, Seres Therapeutics, Inc. had 0 approved new consortium programs in this pipeline, so the bucket was still pure optionality, not earnings. The same engineering engine could still spawn new microbiome consortia, but each candidate would need to prove safety, stability, and efficacy before it could matter.\u003c\/p\u003e\n\u003cp\u003eThat makes this a classic Question Mark in BCG terms: low share, high possible upside, and high technical risk. With 2025 still speculative, the right read was discovery value, not commercial value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 approved new consortium assets\u003c\/li\u003e\n\u003cli\u003eDiscovery platform still had upside\u003c\/li\u003e\n\u003cli\u003eEnd-2025 status was speculative\u003c\/li\u003e\n\u003cli\u003eLow share, high risk, possible payoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-155: Promising but Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025, Seres Therapeutics, Inc.’s Question Marks were still led by SER-155: a Phase Ib asset with $0 commercial revenue and no market share. It showed a 77% relative drop in bloodstream infections vs controls in allo-HSCT, but larger proof was still missing.\u003c\/p\u003e\n\u003cp\u003eThe same logic applied to GVHD prevention and the microbiome platform: high unmet need, but no approved revenue base or validated standard-of-care role yet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-155\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBSI reduction\u003c\/td\u003e\n\u003ctd\u003e77%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG fit\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234628509961,"sku":"mcrb-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mcrb-bcg-matrix.webp?v=1785724738","url":"https:\/\/dcfanalyst.com\/products\/mcrb-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}